Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study

被引：0

作者：

Flowers, Christopher

Zinzani, Pier Luigi

Mayer, Jiri

Bijou, Fontanet

de Oliveira, Ana C.

Song, Yuqin

Zhang, Qingyuan

Merli, Michele

Bouabdallah, Krimo

Ganly, Peter S.

Zhang, Huilai

Yuen, Sam

Kingsley, Ed

Assouline, Sarit E.

Auer, Rebecca

Kim, Pil

Greenbaum, Adam

Huang, Sha

Delarue, Richard

Trotman, Judith

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[2] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[3] Masaryk Univ, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[4] Univ Hosp, Brno, Czech Republic

[5] Inst Bergonie, Bordeaux, France

[6] Hosp Duran I Reynals, Inst Catala Oncol ICO, Barcelona, Spain

[7] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[8] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[9] Univ Insubria, Univ Hosp Osped Circolo & Fdn Macchi ASST Sette L, Hematol, Varese, Italy

[10] CHU Bordeaux, Hop Haut Leveque, Pessac, France

[11] Christchurch Hosp, Dept Haematol, Christchurch, New Zealand

[12] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[13] Calvary Mater Newcastle, Waratah, NSW, Australia

[14] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[15] Jewish Gen Hosp, Montreal, PQ, Canada

[16] Barts Hlth NHS Trust, St Bartholomews Hosp, London, England

[17] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[18] BeiGene USA Inc, San Mateo, CA USA

[19] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7545

引用

页数：1